PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 28, 2025ACS Omega10 citationsOpen Access

Modeling Ischemia-Reperfusion Injury in Stroke Using the BBB Chip

View Full Paper
YWYunsong WuMZMin ZhangPWPeng Wang

Key Points

  • The ischemic stroke model showed significant blood-brain barrier destruction and mitochondrial dysfunction, indicating severe injury.
  • Transcriptome sequencing revealed dysregulated gene expression in pathways related to autophagy and oxidative stress, suggesting complex injury mechanisms.
  • Experiments tested drug impacts, where acetazolamide and edaravone significantly reduced ischemic injury, improving recovery.
  • The innovative microfluidic approach offers a promising platform for testing therapeutic drugs related to ischemic stroke.

Abstract

Ischemic stroke is a leading cause of disability worldwide and poses a serious threat to public health, affecting tens of millions of people all over the world per year. The lack of a humanized organ model reflecting the real situation of patients has quite limited the pathogenesis research and therapeutic drug development of ischemic stroke. In this study, we developed an ischemic stroke model based on a high-throughput microfluidic chip device, simulating ischemia-reperfusion injury in an ischemic stroke. In this ischemic stroke model, we observed a series of injury characteristics, including significant blood–brain barrier (BBB) destruction, cell apoptosis, and mitochondrial dysfunction. Transcriptome sequencing analysis showed that the expression of genes involved in autophagy, oxidative stress, angiogenesis, and other related pathways was significantly dysregulated in the ischemic stroke model. Drug screening experiments revealed that acetazolamide (AZA), edaravone (EDA), and fasudil (FAS) could significantly reduce the damage in an ischemic stroke model. Overall, the ischemic stroke model recapitulated the physiological and pathological responses of ischemic stroke, and it was innovative that our model focused on reperfusion injury using microfluidic organ-on-a-chip technology. This ischemic stroke brain model holds promise for advancing the development and testing of therapeutic drugs for ischemic stroke, thus contributing to the evolution of treatment strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/68d8f313d88e2624dc4c5566https://doi.org/10.1021/acsomega.5c06071
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global, regional, and national burden of ischemic stroke, 1990–2021: an analysis of data from the global burden of disease study 20212024 · 355 citations
  2. 2Neuroprotection by selective neuronal deletion of Atg7 in neonatal brain injury2016 · 161 citations
  3. 3Thrombolytic agents2005 · 140 citations
  4. 4Cathepsin B knockout confers significant brain protection in the mouse model of stroke2023 · 7 citations
  5. 5The role of the low-density lipoprotein receptor–related protein 1 (LRP-1) in regulating blood-brain barrier integrity2016 · 120 citations